Through groundbreaking research and technology, we are reshaping what it means to treat burgeoning global populations with age-related chronic diseases

Scroll

At Filamon, we are pioneering a bold, science-driven approach to address chronic inflammatory and degenerative diseases – conditions that continue to increasingly impact millions worldwide, particularly as we age. Our focus is on providing the aging global generation with a renewed chance for productive, improved quality of life, and independent living.

OUR COMPANY

Our research approach treats chronic inflammatory and degenerative diseases, not as isolated conditions, but as interconnected outcomes stemming from decades of exposure of the body to low-grade inflammation.

From debilitating conditions affecting the heart, lungs, kidneys, eyes and joints to life-threatening conditions like cancer and dementia, we believe these diseases stem from the same underlying processes. By targeting inflammation at its core, Filamon drugs are intended to address multiple conditions, providing powerful treatment options for the aging population many of whom suffer from two or more chronic diseases.

Our Science

Filamon is developing a pipeline of technology platforms designed to target the ‘master switches’ of chronic inflammation, with a focus on age-related degenerative diseases. The company utilizes three proprietary, novel drug technology platforms designed to address complex inflammation from different angles. By using three distinct, novel approaches, the Company is not relying on a single mechanism of action, increasing the likelihood of achieving a successful therapeutic outcome.

ALPHA

ALPHA drugs are designed to address the paradox of chronic diseases being a mix of over-active protein-protein interactions associated with inflammation and under-activity associated with degenerative disease processes.

Find Out More

BETA

BETA drugs are a novel class of anti-inflammatory therapies that act through the MEK–ERK signalling pathway, a key intracellular driver of chronic inflammation. Filamon has developed a way to regulate this pathway in inflamed tissue while minimising effects on healthy tissue, creating new opportunities for MEK–ERK inhibitors in chronic disease. The BETA platform is being advanced for cancer, cardiovascular disease, and neuroinflammatory conditions including macular degeneration and uveitis.

Find Out More

SIGMA

SIGMA drugs are a first-in-class family of inhibitors targeting proteins that display prion-like behaviour, characterised by misfolding, stickiness and the formation of toxic aggregates. This degenerative process is a major contributor to neurodegenerative diseases, including dementia and degenerative eye conditions. The SIGMA platform is being developed for dry macular degeneration and geographic atrophy.

Find Out More
OUR DIFFERENCE

The Filamon Difference: Multi-modal Therapies for Complex Diseases

The challenge for conventional anti-inflammatory treatments is that many are products of the era of ‘precision’ or ‘targeted’ medicine, or so-called mono-modal drugs designed purposely to act on single pathways or genes. However, chronic inflammation that has developed over years involves hundreds of genes that is far too complex for drugs with limited ranges of function.

Our breakthrough solution lies in three multi-modal technology platforms capable of influencing hundreds of pro-inflammatory proteins and genes simultaneously. This innovation enables Filamon to design drugs that address chronic inflammation at its root, offering new hope for patients with conditions once considered intractable.

Each of the three technology platforms addresses the problem from different angles, although with a high degree of cross-over, giving Filamon significant risk-mitigation in its quest to develop the next generation of anti-inflammatory drugs.

Our Pipeline

Redefining Age-Related Disease Treatment with Next-Generation Anti-Inflammatory Drugs Targeting Complex Gene Networks

KESONOTIDE™

Find Out More

BETA-TT8

Find Out More

Our Mission

Our mission is to redefine chronic disease treatment, offering powerful, multimodal therapies that transform patients’ lives.

We are dedicated to empowering those living with chronic inflammatory diseases by delivering innovative medicines that alleviate pain, foster independence, and promote active, fulfilling lives.

Subscribe to receive
the latest news and updates
This field is for validation purposes and should be left unchanged.